文献速递湿疹皮炎与荨麻疹

芦可替尼乳膏治疗特应性皮炎的两项3期随机双盲研究

Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
PubMed 文献 · J Am Acad Dermatol · 2021-05-04

两种浓度在第8周IGA治疗成功率均显著优于赋形剂,1.5%浓度首次涂抹后12小时内即显著止痒,耐受性良好。

要点

  • 0.75%和1.5%芦可替尼乳膏每日两次治疗8周,IGA治疗成功率显著优于赋形剂。
  • 1.5%芦可替尼乳膏首次涂抹后12小时内即出现显著瘙痒改善。
  • 应用部位反应发生率低于1%,且芦可替尼组低于赋形剂组,无临床显著反应。

核心结论

  • 芦可替尼乳膏具有抗炎和快速止痒作用,疗效优于赋形剂且耐受性良好。

研究设计与样本

  • 两项3期随机双盲赋形剂对照研究(研究1 NCT03745638、研究2 NCT03745651)。
  • 纳入年龄≥12岁、AD病程≥2年、IGA评分2/3、受累体表面积3%-20%的患者。
  • 按2:2:1随机分配至每日两次0.75%芦可替尼乳膏、1.5%芦可替尼乳膏或赋形剂乳膏,连续治疗8周。
  • 研究1和研究2分别随机631例和618例患者,疗效分析集分别为631例和577例。

主要发现

  • 第8周IGA治疗成功率:研究1中0.75%组50.0%、1.5%组53.8%、赋形剂组15.1%;研究2中分别为39.0%、51.3%、7.6%(P < .0001)。
  • 1.5%芦可替尼首次涂抹后12小时内瘙痒较赋形剂显著改善(P < .05)。
  • 应用部位反应发生率低于1%,芦可替尼组低于赋形剂组,均无临床显著性。

关键数值与推荐

  • 主要终点为第8周IGA治疗成功,即IGA评分0/1且较基线改善≥2级。

临床怎么用

  • 对于年龄≥12岁、IGA评分2/3且受累体表面积3%-20%的AD患者,可考虑每日两次外用芦可替尼乳膏治疗8周。

局限性

  • 尚缺乏长期安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ruxolitinib (RUX) cream demonstrated potent anti-inflammatory and antipruritic efficacy in a phase 2 study in adults with atopic dermatitis (AD). OBJECTIVE: To evaluate 8-week efficacy and safety in 2 phase 3 studies of RUX cream in patients with AD. METHODS: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (NCT03745638) and Study 2 (NCT03745651) enrolled patients aged ≥12 years with AD for ≥2 years, an Investigator's Global Assessment score of 2/3, and 3%-20% affected body surface area. Patients were randomized 2:2:1 to twice-daily 0.75% RUX cream, 1.5% RUX cream, or vehicle cream for 8 continuous weeks. The primary endpoint was Investigator's Global Assessment treatment success at week 8 (Investigator's Global Assessment score of 0/1 and ≥2-grade improvement from baseline). RESULTS: In the Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 and 2, 631 and 618 patients were randomized (631/577 analyzed for efficacy). Significantly more patients achieved Investigator's Global Assessment treatment success with 0.75% RUX cream (50.0%/39.0%) and 1.5% RUX cream (53.8%/51.3%) versus vehicle (15.1%/7.6%; P < .0001) at week 8. Significant itch reductions versus vehicle were reported within 12 hours of first application of 1.5% RUX (P < .05). Application site reactions were infrequent (<1%) and lower with RUX versus vehicle; none were clinically significant. LIMITATIONS: Longer-term safety data are not yet available. CONCLUSIONS: RUX cream showed anti-inflammatory and prompt antipruritic effects with superior efficacy versus vehicle and was well tolerated.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021. PMID: 33957195. doi:10.1016/j.jaad.2021.04.085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。